0001104659-24-044305.txt : 20240405 0001104659-24-044305.hdr.sgml : 20240405 20240405163226 ACCESSION NUMBER: 0001104659-24-044305 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20240405 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240405 DATE AS OF CHANGE: 20240405 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Global Medical REIT Inc. CENTRAL INDEX KEY: 0001533615 STANDARD INDUSTRIAL CLASSIFICATION: REAL ESTATE INVESTMENT TRUSTS [6798] ORGANIZATION NAME: 05 Real Estate & Construction IRS NUMBER: 464757266 STATE OF INCORPORATION: MD FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37815 FILM NUMBER: 24826968 BUSINESS ADDRESS: STREET 1: 7373 WISCONSIN AVENUE STREET 2: SUITE 800 CITY: BETHESDA STATE: MD ZIP: 20814 BUSINESS PHONE: 202-524-6851 MAIL ADDRESS: STREET 1: 7373 WISCONSIN AVENUE STREET 2: SUITE 800 CITY: BETHESDA STATE: MD ZIP: 20814 FORMER COMPANY: FORMER CONFORMED NAME: SCOOP MEDIA, INC. DATE OF NAME CHANGE: 20111027 8-K 1 tm2411103d1_8k.htm FORM 8-K
false 0001533615 0001533615 2024-04-05 2024-04-05 0001533615 us-gaap:CommonStockMember 2024-04-05 2024-04-05 0001533615 us-gaap:SeriesAPreferredStockMember 2024-04-05 2024-04-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): April 5, 2024

 

Global Medical REIT Inc.

(Exact name of registrant as specified in its charter)

 

Maryland 001-37815 46-4757266
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification No.)

 

7373 Wisconsin Avenue, Suite 800

Bethesda, MD

20814

(Address of Principal Executive
Offices)

(Zip Code)

 

(202) 524-6851

(Registrant’s Telephone Number, Including Area Code)

 

Not Applicable

(Former name or former address, if changed since last report)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class:   Trading Symbols:   Name of each exchange on which registered:
Common Stock, par value $0.001 per share   GMRE   NYSE
Series A Preferred Stock, par value $0.001 per share   GMRE PrA   NYSE

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

Item 8.01 Other Events.

 

On April 5, 2024, Global Medical REIT Inc. (the “Company”) filed a prospectus supplement (the “Prospectus Supplement”) in connection with its “at the market offering” program (the “ATM Program”) pursuant to the Company’s registration statement on Form S-3ASR (File No. 333-276248), as amended by Post-Effective Amendment No. 1 (“Post-Effective Amendment No. 1”) and Post-Effective Amendment No. 2 (“Post-Effective Amendment No. 2”) thereto. The Company filed the Prospectus Supplement solely to move the ATM Program from Post-Effective Amendment No. 1 to Post-Effective Amendment No. 2, which Post-Effective Amendment No. 2 was filed because the Company no longer qualified as a “well-known seasoned issuer” (as such term is defined in Rule 405 of the Securities Act of 1933, as amended) when it filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2023. The opinion of Venable LLP, counsel to the Company, is filed as Exhibit 5.1 to this Report and is incorporated by reference to the Prospectus Supplement.

 

Item 9.01 Financial Statements and Exhibits.

 

(d)  Exhibits

 

Exhibit No.   Description
5.1   Opinion of Venable LLP.
23.1   Consent of Venable LLP (included in Exhibit 5.1).
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

  

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Global Medical REIT Inc.
     
  By:   /s/ Jamie A. Barber
    Jamie A. Barber
    Secretary and General Counsel

 

Date: April 5, 2024

 

 

 

EX-5.1 2 tm2411103d1_ex5-1.htm EXHIBIT 5.1

 

Exhibit 5.1

 

 

 

April 5, 2024

 

Global Medical REIT Inc. 

7373 Wisconsin Avenue 

Suite 800 

Bethesda, MD 20814

 

Re:     Registration Statement on Form S-3 (File No. 333-276248)

 

Ladies and Gentlemen:

  

We have served as Maryland counsel to Global Medical REIT Inc., a Maryland corporation (the “Company”), in connection with certain matters of Maryland law arising out of the registration and issuance by the Company of shares (the “Shares”) of common stock, $0.001 par value per share, of the Company (the “Common Stock”), having an aggregate offering price of up to $300,000,000. The Shares are covered by the Registration Statement on Form S-3, and all amendments thereto (the “Registration Statement”), as filed with the U.S. Securities and Exchange Commission (the “Commission”) by the Company under the Securities Act of 1933, as amended (the “1933 Act”).

 

In connection with our representation of the Company, and as a basis for the opinion hereinafter set forth, we have examined originals, or copies certified or otherwise identified to our satisfaction, of the following documents (hereinafter collectively referred to as the “Documents”):

 

1.            The Registration Statement, and the related form of prospectus contained therein, in the form in which it was transmitted to the Commission under the 1933 Act;

2.            The Prospectus Supplement, dated as of April 5, 2024;

3.            The charter of the Company (the “Charter”), certified by the State Department of Assessments and Taxation of Maryland (the “SDAT”);

4.            The Fourth Amended and Restated Bylaws of the Company (the “Bylaws”), certified as of the date hereof by an officer of the Company;

5.            A certificate of the SDAT as to the good standing of the Company, dated as of a recent date;

6.            Resolutions (the “Resolutions”) adopted by the Board of Directors of the Company (the “Board”), relating to, among other matters, the sale and issuance of the Shares and any Forward Settlement Shares (as defined in the Sales Agreement), certified as of the date hereof by an officer of the Company;

7.            A certificate executed by an officer of the Company, dated as of the date hereof;

Global Medical REIT Inc. 

April 5, 2024 

Page 2

8.            The Sales Agreement, dated as of January 9, 2024 (the “Sales Agreement”), by and among the Company, Global Medical REIT, L.P., and (a) BMO Capital Markets Corp., B. Riley Securities, Inc., Robert W. Baird & Co. Incorporated, Berenberg Capital Markets LLC, Colliers Securities LLC, Compass Point Research & Trading, LLC, Janney Montgomery Scott LLC, Citizens JMP Securities, LLC, J.P. Morgan Securities LLC, KeyBanc Capital Markets Inc., Samuel A. Ramirez & Company, Inc., Stifel, Nicolaus & Company, Incorporated, Truist Securities, Inc. and Wells Fargo Securities, LLC (each individually an “Agent” and collectively, the “Agents”), (b) Bank of Montreal, B. Riley Securities, Inc., Robert W. Baird & Co. Incorporated, Citizens JMP Securities, LLC, JPMorgan Chase Bank, National Association, KeyBanc Capital Markets Inc., Stifel, Nicolaus & Company, Incorporated, Truist Bank and Wells Fargo Bank, National Association (each individually a “Forward Purchaser” and, collectively, the “Forward Purchasers”) and (c) BMO Capital Markets Corp., B. Riley Securities, Inc., Robert W. Baird & Co. Incorporated, Citizens JMP Securities, LLC, J.P. Morgan Securities LLC, KeyBanc Capital Markets Inc., Stifel, Nicolaus & Company, Incorporated, Truist Securities, Inc. and Wells Fargo Securities, LLC (each individually a “Forward Seller” and, collectively the “Forward Sellers”);

9.            The Master Forward Confirmations for Issuer Forward Sale Transactions listed on Schedule I hereto, each dated as of the date hereof (the “Master Forward Confirmations”), each by and among the Company, the applicable Agent and the applicable Forward Purchasers;

10.          The form of supplemental confirmation (the “Supplemental Confirmation”), included as an exhibit to each Master Forward Confirmation, to be executed in connection with the issuance of any Forward Settlement Shares pursuant to a Master Forward Confirmation;

11.          The form of Terms Agreement (the “Terms Agreement”), included as an exhibit to the Sales Agreement, to be executed in connection with the issuance of any Shares to an Agent, as principal; and

12.          Such other documents and matters as we have deemed necessary or appropriate to express the opinion set forth in this letter, subject to the assumptions, limitations and qualifications stated herein.

In expressing the opinion set forth below, we have assumed the following:

1.            Each individual executing any of the Documents, whether on behalf of such individual or another person, is legally competent to do so.

Global Medical REIT Inc. 

April 5, 2024 

Page 3

2.            Each individual executing any of the Documents on behalf of a party (other than the Company) is duly authorized to do so.

3.            Each of the parties (other than the Company) executing any of the Documents has duly and validly executed and delivered each of the Documents to which such party is a signatory, and such party’s obligations set forth therein are legal, valid and binding and are enforceable in accordance with all stated terms.

4.            All Documents submitted to us as originals are authentic. The form and content of all Documents submitted to us as unexecuted drafts do not differ in any respect relevant to this opinion from the form and content of such Documents as executed and delivered. All Documents submitted to us as certified or photostatic copies conform to the original documents. All signatures on all Documents are genuine. All public records reviewed or relied upon by us or on our behalf are true and complete. All representations, warranties, statements and information contained in the Documents are true and complete. There has been no oral or written modification of or amendment to any of the Documents, and there has been no waiver of any provision of any of the Documents, by action or omission of the parties or otherwise.

5.            Upon the issuance of any of the Shares and any Forward Settlement Shares, the total number of shares of Common Stock issued and outstanding will not exceed the total number of shares of Common Stock that the Company is then authorized to issue under the Charter.

6.            Prior to the issuance of any of the Shares to be issued pursuant to the Sales Agreement (and, if applicable, the related Terms Agreement) or any Forward Settlement Shares to be issued pursuant to the Master Forward Confirmations (and the related Supplemental Confirmation), as applicable, the Board, a duly authorized pricing committee of the Board or a duly authorized officer of the Company will determine the price and certain other terms of issuance of such Shares or Forward Settlement Shares, as applicable, in accordance with and not in violation of the Maryland General Corporation Law, the Charter, the Bylaws, the Registration Statement and the Resolutions (the “Corporate Proceedings”).

7.            None of the Shares or the Forward Settlement Shares will be issued, sold or transferred in violation of the restrictions on ownership and transfer set forth in Article VII of the Charter.

Based upon the foregoing, and subject to the assumptions, limitations and qualifications stated herein, it is our opinion that:

1.            The Company is a corporation duly incorporated and existing under and by virtue of the laws of the State of Maryland and is in good standing with the SDAT.

Global Medical REIT Inc. 

April 5, 2024 

Page 4

2.            The issuance of the Shares and the Forward Settlement Shares has been duly authorized and, when issued and delivered by the Company in accordance with the Sales Agreement (and, if applicable, the related Terms Agreement) or the Master Forward Confirmations (and related Supplemental Confirmation), as applicable, the Resolutions, the Corporate Proceedings and the Registration Statement against payment of the consideration set forth therein, the Shares and the Forward Settlement Shares will be validly issued, fully paid and nonassessable.

  

The foregoing opinion is limited to the laws of the State of Maryland and we do not express any opinion herein concerning United States federal law or the laws of any other jurisdiction. We express no opinion as to the applicability or effect of federal or state securities laws, including the securities laws of the State of Maryland, or as to federal or state laws regarding fraudulent transfers. To the extent that any matter as to which our opinion is expressed herein would be governed by any jurisdiction other than the State of Maryland, we do not express any opinion on such matter. The opinion expressed herein is subject to the effect of any judicial decision which may permit the introduction of parol evidence to modify the terms or the interpretation of agreements.

The opinion expressed herein is limited to the matters specifically set forth herein and no other opinion shall be inferred beyond the matters expressly stated. We assume no obligation to supplement this opinion if any applicable law changes after the date hereof or if we become aware of any fact that might change the opinion expressed herein after the date hereof.

This opinion is being furnished to you for submission to the Commission as an exhibit to the Company’s Current Report on Form 8-K (the “Current Report”), which is incorporated by reference in the Registration Statement. We hereby consent to the filing of this opinion as an exhibit to the Current Report and to the use of the name of our firm therein. In giving this consent, we do not admit that we are within the category of persons whose consent is required by Section 7 of the 1933 Act.

Very truly yours,
/s/ Venable LLP

  

Schedule I

1.            The Master Confirmation for Issuer Share Forward Sale Transactions, by and between the Company and Bank of Montreal and BMO Capital Markets Corp., solely in its capacity as agent for Bank of Montreal;

2.            The Master Confirmation for Issuer Share Forward Sale Transactions, by and between the Company and B. Riley Securities, Inc.;

3.            The Master Confirmation for Issuer Share Forward Sale Transactions, by and between the Company and Robert W. Baird & Co. Incorporated;

4.            The Master Confirmation for Issuer Share Forward Sale Transactions, by and between the Company and Citizens JMP Securities, LLC;

5.            The Master Confirmation for Issuer Share Forward Sale Transactions, by and between the Company and JPMorgan Chase Bank, National Association;

6.            The Master Confirmation for Issuer Share Forward Sale Transactions, by and between the Company and KeyBanc Capital Markets Inc.;

7.            The Master Confirmation for Issuer Share Forward Sale Transactions, by and between the Company and Stifel, Nicolaus & Company Incorporated;

8.            The Master Confirmation for Issuer Share Forward Sale Transactions, by and between the Company and Truist Bank; and

9.            The Master Confirmation for Issuer Share Forward Sale Transactions, by and between the Company and Wells Fargo Bank, National Association.

EX-101.SCH 3 gmre-20240405.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 gmre-20240405_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 gmre-20240405_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Class of Stock [Axis] Common Stock [Member] Series A Preferred Stock [Member] Statement [Table] Document Information [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 gmre-20240405_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 tm2411103_ex5-1img001.jpg GRAPHIC begin 644 tm2411103_ex5-1img001.jpg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end GRAPHIC 8 tm2411103_ex5-1img002.jpg GRAPHIC begin 644 tm2411103_ex5-1img002.jpg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htm IDEA: XBRL DOCUMENT v3.24.1
Cover
Apr. 05, 2024
Document Information [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Apr. 05, 2024
Entity File Number 001-37815
Entity Registrant Name Global Medical REIT Inc.
Entity Central Index Key 0001533615
Entity Tax Identification Number 46-4757266
Entity Incorporation, State or Country Code MD
Entity Address, Address Line One 7373 Wisconsin Avenue
Entity Address, Address Line Two Suite 800
Entity Address, City or Town Bethesda
Entity Address, State or Province MD
Entity Address, Postal Zip Code 20814
City Area Code 202
Local Phone Number 524-6851
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Common Stock [Member]  
Document Information [Line Items]  
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol GMRE
Security Exchange Name NYSE
Series A Preferred Stock [Member]  
Document Information [Line Items]  
Title of 12(b) Security Series A Preferred Stock, par value $0.001 per share
Trading Symbol GMRE PrA
Security Exchange Name NYSE
EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 15 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1 html 3 23 1 false 2 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://globalmedicalreit.com/role/Cover Cover Cover 1 false false All Reports Book All Reports gmre-20240405.xsd gmre-20240405_def.xml gmre-20240405_lab.xml gmre-20240405_pre.xml tm2411103d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 17 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2411103d1_8k.htm": { "nsprefix": "gmre", "nsuri": "http://globalmedicalreit.com/20240405", "dts": { "schema": { "local": [ "gmre-20240405.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "definitionLink": { "local": [ "gmre-20240405_def.xml" ] }, "labelLink": { "local": [ "gmre-20240405_lab.xml" ] }, "presentationLink": { "local": [ "gmre-20240405_pre.xml" ] }, "inline": { "local": [ "tm2411103d1_8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 2, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 3, "entityCount": 1, "segmentCount": 2, "elementCount": 65, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 26 }, "report": { "R1": { "role": "http://globalmedicalreit.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-04-05", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2411103d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-04-05", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2411103d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://globalmedicalreit.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://globalmedicalreit.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://globalmedicalreit.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://globalmedicalreit.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://globalmedicalreit.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://globalmedicalreit.com/role/Cover" ], "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://globalmedicalreit.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://globalmedicalreit.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://globalmedicalreit.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://globalmedicalreit.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://globalmedicalreit.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://globalmedicalreit.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://globalmedicalreit.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://globalmedicalreit.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://globalmedicalreit.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://globalmedicalreit.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://globalmedicalreit.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://globalmedicalreit.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://globalmedicalreit.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://globalmedicalreit.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://globalmedicalreit.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://globalmedicalreit.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://globalmedicalreit.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://globalmedicalreit.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://globalmedicalreit.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://globalmedicalreit.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://globalmedicalreit.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://globalmedicalreit.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://globalmedicalreit.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://globalmedicalreit.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://globalmedicalreit.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://globalmedicalreit.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://globalmedicalreit.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://globalmedicalreit.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://globalmedicalreit.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://globalmedicalreit.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://globalmedicalreit.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://globalmedicalreit.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://globalmedicalreit.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://globalmedicalreit.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://globalmedicalreit.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://globalmedicalreit.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://globalmedicalreit.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://globalmedicalreit.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://globalmedicalreit.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://globalmedicalreit.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://globalmedicalreit.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://globalmedicalreit.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://globalmedicalreit.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://globalmedicalreit.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://globalmedicalreit.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://globalmedicalreit.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://globalmedicalreit.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://globalmedicalreit.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://globalmedicalreit.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://globalmedicalreit.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://globalmedicalreit.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://globalmedicalreit.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "us-gaap_SeriesAPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeriesAPreferredStockMember", "presentation": [ "http://globalmedicalreit.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Series A Preferred Stock [Member]" } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://globalmedicalreit.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://globalmedicalreit.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://globalmedicalreit.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://globalmedicalreit.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://globalmedicalreit.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 18 0001104659-24-044305-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-24-044305-xbrl.zip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tm2411103d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001533615 2024-04-05 2024-04-05 0001533615 us-gaap:CommonStockMember 2024-04-05 2024-04-05 0001533615 us-gaap:SeriesAPreferredStockMember 2024-04-05 2024-04-05 iso4217:USD shares iso4217:USD shares false 0001533615 8-K 2024-04-05 Global Medical REIT Inc. MD 001-37815 46-4757266 7373 Wisconsin Avenue Suite 800 Bethesda MD 20814 202 524-6851 false false false false Common Stock, par value $0.001 per share GMRE NYSE Series A Preferred Stock, par value $0.001 per share GMRE PrA NYSE false